vs
Side-by-side financial comparison of C3.ai, Inc. (AI) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $75.1M, roughly 1.7× C3.ai, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -20.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -2.1%).
C3.ai, Inc. is a leading enterprise artificial intelligence software provider that develops and delivers scalable AI applications, platform tools, and industry-specific solutions for clients across sectors including manufacturing, energy, financial services, healthcare and public sector. Its offerings help organizations optimize operations, reduce costs, mitigate risks, and realize data-driven decision making.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
AI vs TVTX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $129.7M |
| Net Profit | $-104.7M | — |
| Gross Margin | 40.4% | 98.0% |
| Operating Margin | -149.2% | -25.0% |
| Net Margin | -139.3% | — |
| Revenue YoY | -20.3% | 73.4% |
| Net Profit YoY | -58.7% | — |
| EPS (diluted) | $-0.75 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $129.7M | ||
| Q3 25 | $70.3M | $164.9M | ||
| Q2 25 | $108.7M | $114.4M | ||
| Q1 25 | $98.8M | $81.7M | ||
| Q4 24 | $94.3M | $74.8M | ||
| Q3 24 | $87.2M | $62.9M | ||
| Q2 24 | $86.6M | $54.1M | ||
| Q1 24 | $78.4M | $41.4M |
| Q4 25 | $-104.7M | — | ||
| Q3 25 | $-116.8M | $25.7M | ||
| Q2 25 | $-79.7M | $-12.8M | ||
| Q1 25 | $-80.2M | $-41.2M | ||
| Q4 24 | $-66.0M | — | ||
| Q3 24 | $-62.8M | $-54.8M | ||
| Q2 24 | $-72.9M | $-70.4M | ||
| Q1 24 | $-72.6M | $-136.1M |
| Q4 25 | 40.4% | 98.0% | ||
| Q3 25 | 37.6% | 99.0% | ||
| Q2 25 | 62.1% | 98.7% | ||
| Q1 25 | 59.1% | 94.3% | ||
| Q4 24 | 61.3% | 96.6% | ||
| Q3 24 | 59.8% | 97.4% | ||
| Q2 24 | 59.6% | 96.2% | ||
| Q1 24 | 57.8% | 96.4% |
| Q4 25 | -149.2% | -25.0% | ||
| Q3 25 | -177.7% | 15.1% | ||
| Q2 25 | -81.8% | -11.1% | ||
| Q1 25 | -88.7% | -52.2% | ||
| Q4 24 | -79.8% | -81.2% | ||
| Q3 24 | -83.2% | -89.3% | ||
| Q2 24 | -95.1% | -125.1% | ||
| Q1 24 | -105.3% | -336.5% |
| Q4 25 | -139.3% | — | ||
| Q3 25 | -166.2% | 15.6% | ||
| Q2 25 | -73.3% | -11.1% | ||
| Q1 25 | -81.2% | -50.4% | ||
| Q4 24 | -69.9% | — | ||
| Q3 24 | -72.0% | -87.1% | ||
| Q2 24 | -84.2% | -130.1% | ||
| Q1 24 | -92.6% | -328.9% |
| Q4 25 | $-0.75 | $0.04 | ||
| Q3 25 | $-0.86 | $0.28 | ||
| Q2 25 | $-0.60 | $-0.14 | ||
| Q1 25 | $-0.62 | $-0.47 | ||
| Q4 24 | $-0.52 | $-0.71 | ||
| Q3 24 | $-0.50 | $-0.70 | ||
| Q2 24 | $-0.59 | $-0.91 | ||
| Q1 24 | $-0.60 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $675.0M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $771.9M | $114.8M |
| Total Assets | $961.3M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $675.0M | $93.0M | ||
| Q3 25 | $711.9M | $110.9M | ||
| Q2 25 | $742.7M | $75.2M | ||
| Q1 25 | $724.3M | $61.9M | ||
| Q4 24 | $730.4M | $58.5M | ||
| Q3 24 | $762.5M | $36.4M | ||
| Q2 24 | $750.4M | $32.3M | ||
| Q1 24 | $723.3M | $43.3M |
| Q4 25 | $771.9M | $114.8M | ||
| Q3 25 | $798.8M | $73.6M | ||
| Q2 25 | $838.3M | $32.7M | ||
| Q1 25 | $860.2M | $32.8M | ||
| Q4 24 | $859.0M | $59.1M | ||
| Q3 24 | $874.9M | $-30.5M | ||
| Q2 24 | $873.4M | $15.1M | ||
| Q1 24 | $898.0M | $74.1M |
| Q4 25 | $961.3M | $605.2M | ||
| Q3 25 | $968.7M | $538.6M | ||
| Q2 25 | $1.0B | $555.3M | ||
| Q1 25 | $1.1B | $548.8M | ||
| Q4 24 | $1.0B | $594.1M | ||
| Q3 24 | $1.1B | $504.4M | ||
| Q2 24 | $1.0B | $551.1M | ||
| Q1 24 | $1.1B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.5M | $60.7M |
| Free Cash FlowOCF − Capex | $-46.9M | — |
| FCF MarginFCF / Revenue | -62.4% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.5M | $60.7M | ||
| Q3 25 | $-33.5M | $14.3M | ||
| Q2 25 | $11.3M | $5.0M | ||
| Q1 25 | $-22.0M | $-42.2M | ||
| Q4 24 | $-38.7M | $-35.7M | ||
| Q3 24 | $8.0M | $-42.5M | ||
| Q2 24 | $21.3M | $-40.2M | ||
| Q1 24 | $-39.1M | $-119.0M |
| Q4 25 | $-46.9M | — | ||
| Q3 25 | $-34.3M | $14.2M | ||
| Q2 25 | $10.3M | — | ||
| Q1 25 | $-22.4M | — | ||
| Q4 24 | $-39.5M | — | ||
| Q3 24 | $7.1M | — | ||
| Q2 24 | $18.8M | $-40.3M | ||
| Q1 24 | $-45.1M | — |
| Q4 25 | -62.4% | — | ||
| Q3 25 | -48.8% | 8.6% | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | -22.7% | — | ||
| Q4 24 | -41.9% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 21.7% | -74.5% | ||
| Q1 24 | -57.6% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 1.1% | 0.1% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 2.9% | 0.2% | ||
| Q1 24 | 7.8% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AI
| License And Service | $70.2M | 93% |
| Professional Services | $4.9M | 7% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
